Pitavastatin Enhances the Anti-Fibrogenesis Effects of Candesartan, an Angiotensin II Receptor Blocker, on CCl4-Induced Liver Fibrosis in Rats
|
Accession number;04A0446530
|
| Title;Pitavastatin Enhances the Anti-Fibrogenesis Effects of Candesartan, an Angiotensin II Receptor Blocker, on CCl4-Induced Liver Fibrosis in Rats |
| Author;
NIE L
(Univ. Occupational And Environmental Health, Kitakyushu, Jpn)
IMAMURA M
(Univ. Occupational And Environmental Health, Kitakyushu, Jpn)
ITOH H
(Univ. Occupational And Environmental Health, Kitakyushu, Jpn)
UENO H
(Univ. Occupational And Environmental Health, Kitakyushu, Jpn)
|
Journal Title;J UOEH Occup Environ Health
|
Journal Code:Z0840A
|
ISSN:0387-821X
|
|
VOL.26;NO.2;PAGE.165-177(2004)
|
| Figure&Table&Reference;FIG.4, TBL.1, REF.30 |
| Pub. Country;Japan |
| Language;English |
| Abstract;It has been shown that a statin (3-hydroxy-3-methyl-glutaryl coenzyme reductase inhibitor) enhances a suppressive effect of angiotensin II type 1 receptor (AT1-R) blocker (ARB) on injury-induced transforming growth factor (TGF)-.BETA. expression in kidneys. We have shown that TGF-.BETA. plays a crucial role in the development of liver fibrosis. In this study, we tested whether a combinatory use of a statin (pitavastatin) and an ARB (candesartan) may further inhibit liver fibrogenesis in carbon tetrachloride (CCl4)-treated rats. Candesartan (8mg/kg/day) significantly suppressed injury-induced TGF-.BETA.1 expression in livers, and attenuated fibrogenesis, as evaluated by masson-trichrome staining and hydroxyproline content in livers. Pitavastatin (2mg/kg/day) alone did not affect liver fibrogenesis. However, it enhanced significantly the suppressive effects of candesartan on TGF-.BETA.1 expression and fibrogenesis. Although we do not know the underlying molecular mechanisms at this moment, these results suggest that a combinatory use of a statin and an ARB may confer beneficial effects on human liver fibrogenesis. (author abst.) |
|
|
|
Related Articles;
|
|
|
